PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 2478216-0 1989 Circulation of CD34+ hematopoietic stem cells in the peripheral blood of high-dose cyclophosphamide-treated patients: enhancement by intravenous recombinant human granulocyte-macrophage colony-stimulating factor. Cyclophosphamide 83-99 CD34 molecule Homo sapiens 15-19 2190884-2 1990 We report that sizable numbers of CD34+ cells transiently circulate in the peripheral blood (PB) of patients treated with high-dose (7 g/sqm) cyclophosphamide (HD-CTX) with or without recombinant human glycosylated granulocyte macrophage colony stimulating factor (rhGM-CSF). Cyclophosphamide 142-158 CD34 molecule Homo sapiens 34-38 34563457-4 2021 However, by adding plerixafor to bortezomib and cyclophosphamide, collected CD34-positive cells were increased six-fold compared to the previous day. Cyclophosphamide 48-64 CD34 molecule Homo sapiens 76-80 34175195-6 2021 CE was superior to cyclophosphamide mono with a significantly higher number of collected CD34+ cells (15.46 x 106 CD34+ cells/kg vs. 9.92 x 106 CD34+ cells/kg), significantly faster engraftment of granulocytes after stem cell transplantation (day 10.5 vs. day 11.6), shorter duration of the inpatient stay (17.47 days vs. 19.16 days) and significantly less transfusions (8.82 % vs. 30.61 % patients receiving transfusions). Cyclophosphamide 19-35 CD34 molecule Homo sapiens 89-93 34175195-6 2021 CE was superior to cyclophosphamide mono with a significantly higher number of collected CD34+ cells (15.46 x 106 CD34+ cells/kg vs. 9.92 x 106 CD34+ cells/kg), significantly faster engraftment of granulocytes after stem cell transplantation (day 10.5 vs. day 11.6), shorter duration of the inpatient stay (17.47 days vs. 19.16 days) and significantly less transfusions (8.82 % vs. 30.61 % patients receiving transfusions). Cyclophosphamide 19-35 CD34 molecule Homo sapiens 114-118 34175195-6 2021 CE was superior to cyclophosphamide mono with a significantly higher number of collected CD34+ cells (15.46 x 106 CD34+ cells/kg vs. 9.92 x 106 CD34+ cells/kg), significantly faster engraftment of granulocytes after stem cell transplantation (day 10.5 vs. day 11.6), shorter duration of the inpatient stay (17.47 days vs. 19.16 days) and significantly less transfusions (8.82 % vs. 30.61 % patients receiving transfusions). Cyclophosphamide 19-35 CD34 molecule Homo sapiens 144-148 35218068-10 2022 RESULTS: Our study noted a higher total and day one CD34+ count in the two groups utilizing cyclophosphamide in mobilization. Cyclophosphamide 92-108 CD34 molecule Homo sapiens 52-56 2478216-1 1989 We report that hematopoietic progenitor cells expressing the CD34 antigen (CD34+ cells) transiently circulate in the peripheral blood (PB) of cancer patients treated with 7 g/m2 cyclophosphamide (HD-CTX) with or without recombinant human granulocyte macrophage-colony stimulating factor (rHuGM-CSF). Cyclophosphamide 178-194 CD34 molecule Homo sapiens 61-65 2478216-1 1989 We report that hematopoietic progenitor cells expressing the CD34 antigen (CD34+ cells) transiently circulate in the peripheral blood (PB) of cancer patients treated with 7 g/m2 cyclophosphamide (HD-CTX) with or without recombinant human granulocyte macrophage-colony stimulating factor (rHuGM-CSF). Cyclophosphamide 178-194 CD34 molecule Homo sapiens 75-79 33658647-0 2021 Impact of infused CD34+ stem cell dosing for allogeneic peripheral blood stem cell transplantation with post-transplant cyclophosphamide. Cyclophosphamide 120-136 CD34 molecule Homo sapiens 18-22 33911199-7 2021 G-CSF + CY mobilisation generated higher median CD34 + yields (8.6 vs. 5.5 x 106/kg, p < 0.001). Cyclophosphamide 8-10 CD34 molecule Homo sapiens 48-52 33204611-1 2020 In CD34+ cells mobilization of patients with multiple myeloma (MM), the use of Cyclophosphamide (CTX) at a dose of 2 g/m2 has low efficacy although also lower toxicity. Cyclophosphamide 79-95 CD34 molecule Homo sapiens 3-7 33592119-10 2021 Patients treated with cytarabine had the highest yield of CD34+ cells (median 7.5 x 106 /kg vs 5.8 and 2.4 for etoposide and cyclophosphamide, P = .001). Cyclophosphamide 125-141 CD34 molecule Homo sapiens 58-62 33592119-11 2021 Higher percentage of patients was able to collect >=2 x 106 CD34+ cells/kg during one leukapheresis after cytarabine (76% vs 21% for cyclophosphamide vs 36% for etoposide, P = .001). Cyclophosphamide 133-149 CD34 molecule Homo sapiens 60-64 27334858-6 2016 A substantial high yield of CD34(+) cells was achieved when patients were treated with a dose-modified IVE regimen, compared with that during the previous regimen (two with the ifosfamide, carboplatin, and etoposide [ICE] regimen, one with high-dose cyclophosphamide and one with the original IVE regimen). Cyclophosphamide 250-266 CD34 molecule Homo sapiens 28-32 32298020-6 2020 RESULTS: The mean peak of CD34+ cells/ul in peripheral blood was 132 (range, 84-202) in Ara-C and 51 (range, 29-69) in Cy cohort (p < 0.001). Cyclophosphamide 119-121 CD34 molecule Homo sapiens 26-30 30670057-17 2019 Use of CD34-selected auto-HSCT with high-dose cyclophosphamide monotherapy as a conditioning regimen may offer an excellent benefit-to-risk balance. Cyclophosphamide 46-62 CD34 molecule Homo sapiens 7-11 26437056-1 2016 The most common means of mobilizing autologous stem cells is G-CSF alone or combined with cyclophosphamide (CY) to obtain sufficient CD34+ cells for one to two transplants. Cyclophosphamide 108-110 CD34 molecule Homo sapiens 133-137 32499108-7 2020 RESULTS: Mobilization with ID - cyclophosphamide and G-CSF resulted in a significantly higher CD34+ peak mean on day 1 yield (119 CD34+ muL vs 67.3; p = 0.06) and in total average CD34+ yield (mean collection 10.6 x 106/kg vs 5.8 x 106/kg; p = 0.004) compared to patients mobilized with G-CSF and plerixafor. Cyclophosphamide 32-48 CD34 molecule Homo sapiens 94-98 32499108-7 2020 RESULTS: Mobilization with ID - cyclophosphamide and G-CSF resulted in a significantly higher CD34+ peak mean on day 1 yield (119 CD34+ muL vs 67.3; p = 0.06) and in total average CD34+ yield (mean collection 10.6 x 106/kg vs 5.8 x 106/kg; p = 0.004) compared to patients mobilized with G-CSF and plerixafor. Cyclophosphamide 32-48 CD34 molecule Homo sapiens 130-134 32499108-7 2020 RESULTS: Mobilization with ID - cyclophosphamide and G-CSF resulted in a significantly higher CD34+ peak mean on day 1 yield (119 CD34+ muL vs 67.3; p = 0.06) and in total average CD34+ yield (mean collection 10.6 x 106/kg vs 5.8 x 106/kg; p = 0.004) compared to patients mobilized with G-CSF and plerixafor. Cyclophosphamide 32-48 CD34 molecule Homo sapiens 130-134 32057615-0 2020 Mobilization kinetics of CD34+ hematopoietic stem cells stimulated by G-CSF and cyclophosphamide in patients with multiple sclerosis who receive an autotransplant. Cyclophosphamide 80-96 CD34 molecule Homo sapiens 25-29 32057615-13 2020 CONCLUSIONS: Mobilization with G-CSF and Cy in MS patients resulted in effective CD34+ hematoprogenitors release from the bone marrow and in intra-apheresis recruitment. Cyclophosphamide 41-43 CD34 molecule Homo sapiens 81-85 31631445-11 2020 Mobilization after <=3 chemotherapy cycles and cycles including cyclophosphamide resulted in a significantly higher yield of CD34+ cells. Cyclophosphamide 64-80 CD34 molecule Homo sapiens 125-129 21894752-1 2011 AIM: To determine an optimal cyclophosphamide dose in the mobilization scheme providing adequate collection of CD34+ cells in patients with multiple myeloma (MM), to optimize the time of initiation of granulocytic colony-stimulating factor (G-CSF) administration, to study effects of induction therapy schemes on results of mobilization and collection of CD34+ cells. Cyclophosphamide 29-45 CD34 molecule Homo sapiens 111-115 25889496-3 2015 METHODS: We aimed to develop a method based on simple clinical parameters for predicting unsuccessful (<2x10(6)/kg) or sub-optimal (<5x10(6)/kg) collections of CD34+ PBSC in newly diagnosed MM patients eligible for AuSCT, treated with novel agents and receiving an homogeneous mobilizing therapy with cyclophosphamide and granulocyte-colony stimulating factor (G-CSF). Cyclophosphamide 307-323 CD34 molecule Homo sapiens 166-170 21894752-21 2011 Cyclophosphamide dose 4 g/m2 provides collection of CD34+ cells number sufficient for two autotransplantations in moderate thrombocytopenia and in less number of substitute transfusions in the absence of serious toxic complications. Cyclophosphamide 0-16 CD34 molecule Homo sapiens 52-56 27863757-4 2016 The objective of this study was to assess the number of CD34+ cells mobilized using granulocyte-colony stimulating factor with and without cyclophosphamide after induction with cyclophosphamide, thalidomide and dexamethasone. Cyclophosphamide 177-193 CD34 molecule Homo sapiens 56-60 25005330-4 2014 After mobilisation with cyclophosphamide and Granulocyte-Colony-Stimulating Factor stem cells were CD34-selected. Cyclophosphamide 24-40 CD34 molecule Homo sapiens 99-103 24525280-2 2014 They generally define peripheral blood cut-off levels of CD34+ cells at a fixed day after starting chemotherapy, mostly with cyclophosphamide. Cyclophosphamide 125-141 CD34 molecule Homo sapiens 57-61 23114516-0 2013 Early measurement of CD34+ cells in peripheral blood after cyclophosphamide and granulocyte colony-stimulating factor treatment predicts later CD34+ mobilisation failure and is a possible criterion for guiding "on demand" use of plerixafor. Cyclophosphamide 59-75 CD34 molecule Homo sapiens 21-25 23114516-10 2013 DISCUSSION: We propose that patients with <6 x 10(6)/L CD34+ cells in peripheral blood on day 12 and <10 x 10(6)/L on day 13 following mobilisation with cyclophosphamide 4 g/m(2) and granulocyte colony-stimulating factor are candidates for "on demand" use of plerixafor, making the administration of this expensive agent more efficient and avoiding its inappropriate use. Cyclophosphamide 159-175 CD34 molecule Homo sapiens 58-62 21894752-1 2011 AIM: To determine an optimal cyclophosphamide dose in the mobilization scheme providing adequate collection of CD34+ cells in patients with multiple myeloma (MM), to optimize the time of initiation of granulocytic colony-stimulating factor (G-CSF) administration, to study effects of induction therapy schemes on results of mobilization and collection of CD34+ cells. Cyclophosphamide 29-45 CD34 molecule Homo sapiens 355-359 21894752-19 2011 CONCLUSION: Administration of high cyclophosphamide doses in combination with G-CSF is an effective and safe method of BHSC mobilization providing collection of adequate number of CD34+ cells for double autotransplantation in 96.8% patients. Cyclophosphamide 35-51 CD34 molecule Homo sapiens 180-184 18608354-10 2008 CD34(+) count on the day of leukapheresis, prior chemotherapy with prednisone, cyclophosphamide, adriamycin and BCNU or melphalan, and stem cell mobilization regimen significantly influenced CD34(+) cell yield. Cyclophosphamide 79-95 CD34 molecule Homo sapiens 191-195 19233728-7 2009 CONCLUSION: Our data suggested that adequate yields of CD34+ cells may be achieved in multiple myeloma or pre-treated Non-Hodgkin"s lymphoma mobilized with low-dose Cy plus G-CSF regardless of the daily monitoring of peripheral blood CD34+ cells. Cyclophosphamide 165-167 CD34 molecule Homo sapiens 55-59 19899124-1 2009 The yield of CD34+ cells collected by apheresis for autologous peripheral blood stem cell (PBSC) transplantation was greatly increased when the appropriate timing was determined to begin using G-CSF after COAEP (Cytoxan, Vinblastine, Arabinosylcytosin, Etoposide and Prednisone) mobilization. Cyclophosphamide 212-219 CD34 molecule Homo sapiens 13-17 16636524-2 2006 During the administration of cyclophosphamide (60 mg/kg/day for 2 days) for mobilization and collection of CD34+ selected peripheral blood stem cells, he developed congestive heart failure. Cyclophosphamide 29-45 CD34 molecule Homo sapiens 107-111 17825150-3 2007 The CD34(+) cells were mobilized with cytoxan (CTX) + granulocyte-colony stimulating factor (G-CSF) and selected by clinical magnetic activated cell sorting (CliniMACS). Cyclophosphamide 38-45 CD34 molecule Homo sapiens 4-8 17763583-14 2007 CONCLUSIONS: Sufficient CD34+ cells can be mobilized by low dose of cyclophosphamide and rhG-CSF. Cyclophosphamide 68-84 CD34 molecule Homo sapiens 24-28 15133484-8 2004 Cyclophosphamide alone is associated with impressive CD34(+) cell yields and clear antimyeloma activity. Cyclophosphamide 0-16 CD34 molecule Homo sapiens 53-57 12732880-5 2003 However, in the stratum of patients who had previously received more than two lines of chemotherapy, CD34+cell peak (P=0.05) and percentage of successful mobilization (P=0.01) were higher when "cyclophosphamide plus G-CSF" was used. Cyclophosphamide 194-210 CD34 molecule Homo sapiens 101-105 15359655-2 2004 After obtaining a partial remission with four cycles of fludarabine at standard dose, the patient underwent to high-dose Cytoxan in order to mobilize CD34+ hematopoietic progenitor cells. Cyclophosphamide 121-128 CD34 molecule Homo sapiens 150-154 12853690-0 2003 Intermediate-dose cyclophosphamide and granulocyte colony-stimulating factor is a valid alternative to high-dose cyclophosphamide for mobilizing peripheral blood CD34+ cells in patients with multiple myeloma. Cyclophosphamide 18-34 CD34 molecule Homo sapiens 162-166 12651270-15 2003 INTERPRETATION AND CONCLUSIONS: CD34+/ASCT using BCNU, Cy and ATG as conditioning regimen has an acceptable toxicity and clearly reduces the progression of MS. Further follow-up is necessary to establish the real impact of this procedure on the long-term evolution of the disease. Cyclophosphamide 55-57 CD34 molecule Homo sapiens 32-36 12853690-0 2003 Intermediate-dose cyclophosphamide and granulocyte colony-stimulating factor is a valid alternative to high-dose cyclophosphamide for mobilizing peripheral blood CD34+ cells in patients with multiple myeloma. Cyclophosphamide 113-129 CD34 molecule Homo sapiens 162-166 11346706-10 2001 Compared to EPI-TAX, mobilization with CY required the overall processing of 30 percent less whole-blood volume to reach the target yield of > or = 10 x 10(6) CD34+ cells per kg of body weight. Cyclophosphamide 39-41 CD34 molecule Homo sapiens 162-166 10954901-3 2000 In this context, we have previously reported that glutathione S-transferase-pi (GST-pi) gene-transduced human CD34(+) cells showed resistance in vitro against 4-hydroperoxicyclophosphamide, an active form of cyclophosphamide (CY). Cyclophosphamide 172-188 CD34 molecule Homo sapiens 110-114 10954901-3 2000 In this context, we have previously reported that glutathione S-transferase-pi (GST-pi) gene-transduced human CD34(+) cells showed resistance in vitro against 4-hydroperoxicyclophosphamide, an active form of cyclophosphamide (CY). Cyclophosphamide 226-228 CD34 molecule Homo sapiens 110-114 9894718-5 1998 Our results showed that after CY a median of 3.6 x 10(6)/kg (0.5-12.8) CD34+ cells were collected with a median of two aphereses in 14 out of 17 patients; three failed to mobilize a number of CD34+ cells adequate for subsequent manipulation. Cyclophosphamide 30-32 CD34 molecule Homo sapiens 71-75 11007917-1 2000 CD34(+) cells and megakaryocyte progenitors were lower in marrow from patients after hematological recovery from the first cycle of 5-fluorouracil, leucovorin, adriamycin, cyclophosphamide (FLAC) chemotherapy plus PIXY321 (GM-CSF/interleukin 3; IL-3 hybrid) than in FLAC + GM-CSF or pre-FLAC marrows. Cyclophosphamide 172-188 CD34 molecule Homo sapiens 0-4 10951848-3 1999 Mobilization with cyclophosphamide and granulocyte-colony stimulating factor was effective in terms of CD34+ cell shift to peripheral blood and the good quality autograft reliably led to haematopoetic recovery after megachemotherapy. Cyclophosphamide 18-34 CD34 molecule Homo sapiens 103-107 10634173-0 1999 CD34+ cell dose requirements for rapid engraftment in a sequential high-dose chemotherapy regimen of paclitaxel, melphalan, and cyclophosphamide, thiotepa, and carboplatin (CTCb) with PBPC support in metastatic breast cancer. Cyclophosphamide 128-144 CD34 molecule Homo sapiens 0-4 10455355-1 1999 This report describes a patient with acute-type adult T cell leukemia/lymphoma (ATLL) successfully treated by autologous CD34+ peripheral blood stem cell transplantation after fractionated total body irradiation and high-dose cytarabine and cyclophosphamide. Cyclophosphamide 241-257 CD34 molecule Homo sapiens 121-125 10037025-2 1999 CD34 positive selection using the CellPro Ceprate CD34 column was performed on PB mononuclear cells obtained after cyclophosphamide/G-CSF mobilization. Cyclophosphamide 115-131 CD34 molecule Homo sapiens 0-4 9535035-9 1998 Cyclophosphamide + G-CSF significantly increased the yield of CD34+ cells but did not increase apoptosis. Cyclophosphamide 0-16 CD34 molecule Homo sapiens 62-66 9728932-9 1998 We conclude that mobilization by cyclophosphamide plus G-CSF leads to a lower number of malignant cells per CD34+ cell in LPs compared with G-CSF alone. Cyclophosphamide 33-49 CD34 molecule Homo sapiens 108-112 9543059-0 1998 CD34+ cells mobilized by cyclophosphamide and granulocyte colony-stimulating factor (G-CSF) are functionally different from CD34+ cells mobilized by G-CSF. Cyclophosphamide 25-41 CD34 molecule Homo sapiens 0-4 9382956-3 1997 In the present study, an attempt was made to endow human stem cell (CD34+ cells) with resistance to cyclophosphamide, a well-known AA, and adriamycin (ADM) by transducing the glutathione-S-transferase pi (GST-pi) gene whose product is thought to detoxify AA by conjugating them with glutathione and to remove a toxic peroxide formed by ADM. Cyclophosphamide 100-116 CD34 molecule Homo sapiens 68-72 9382956-7 1997 The GST-pi gene-transduced CD34+ cells formed almost 3- and 2.5-fold more CFU-GM than neo gene-transduced CD34+ cells in the presence of 2.5 microg/ml of 4-hydroperoxycyclophosphamide (4-HC), an active form of cyclophosphamide, and 30 ng/ml ADM, respectively. Cyclophosphamide 167-183 CD34 molecule Homo sapiens 27-31 9233591-6 1997 The median yield of CD34+ cells per leukapheresis was almost twice as high in patients receiving IVE (1.94 x 10(6)/kg) compared to cyclophosphamide (1.03 x 10(6)/kg) (P = 0.035). Cyclophosphamide 131-147 CD34 molecule Homo sapiens 20-24 9308634-10 1997 CONCLUSION: A regimen of cyclophosphamide, etoposide, and granulocyte-colony-stimulating factor led to the successful collection of adequate numbers of CD34+ cells in most patients without excessive toxicity. Cyclophosphamide 25-41 CD34 molecule Homo sapiens 152-156 9090787-6 1997 Cyclophosphamide (CY) increased the frequency of CD34+ cells and the corresponding MK/MNC yield for both cytokines, but had no effect on the MK/CD34+ yield. Cyclophosphamide 0-16 CD34 molecule Homo sapiens 49-53 9267668-6 1997 The mean daily collection of CD34+ cells was 5.46 x 10(6)/kg for patients receiving 200 mg/m2 of paclitaxel and 3 gm/m2 of Cy as compared to 2.77 for patients receiving the lower doses (p = 0.0005). Cyclophosphamide 123-125 CD34 molecule Homo sapiens 29-33 9163618-3 1997 Most CD34-positive PBPC are quiescent (<1% in S phase) when they are collected from the bloodstream of patients treated with cyclophosphamide and granulocyte colony-stimulating factor (G-CSF), but we have shown that they are able to resume proliferation rapidly in vitro by measuring the kinetics of CFU-GM production by primitive plastic-adherent (Pdelta) cells. Cyclophosphamide 128-144 CD34 molecule Homo sapiens 5-9 9149745-3 1997 Transplantation of CD34+ cells from haploidentical parents was performed after the children were conditioned with fractionated total body irradiation, cyclophosphamide, and antithymocyte globulin (ATG). Cyclophosphamide 151-167 CD34 molecule Homo sapiens 19-23 9090787-6 1997 Cyclophosphamide (CY) increased the frequency of CD34+ cells and the corresponding MK/MNC yield for both cytokines, but had no effect on the MK/CD34+ yield. Cyclophosphamide 18-20 CD34 molecule Homo sapiens 49-53 7528861-8 1994 We conclude that the first progenitors appearing in the peripheral blood after priming with high-dose cyclophosphamide and GM- or G-CSF have a more primitive immunophenotype, CD34+/33-. Cyclophosphamide 102-118 CD34 molecule Homo sapiens 175-179 7579367-13 1995 Patients receiving high-dose cyclophosphamide, thiotepa, and carboplatin had more rapid platelet recovery than patients receiving other regimens (P = .006), and patients requiring 2 mobilization procedures versus 1 mobilization procedure to achieve > or = 2.5 x 10(6) CD34+ cells/kg experienced slower platelet recovery (P = .005). Cyclophosphamide 29-45 CD34 molecule Homo sapiens 271-275 8877715-7 1996 A significantly higher yield of CD34+ cells and a better correlation between CD34+ cells in the peripheral blood and the leukapheresis product were found after priming with high-dose cyclophosphamide plus rhG-CSF, compared with priming with rhG-CSF alone. Cyclophosphamide 183-199 CD34 molecule Homo sapiens 32-36 8877715-7 1996 A significantly higher yield of CD34+ cells and a better correlation between CD34+ cells in the peripheral blood and the leukapheresis product were found after priming with high-dose cyclophosphamide plus rhG-CSF, compared with priming with rhG-CSF alone. Cyclophosphamide 183-199 CD34 molecule Homo sapiens 77-81 7541450-7 1995 The mean daily yield of CD34+ cells/kg/collection was 3.5 (range, 0.8 to 28.9) after Taxol and CY, as compared with 1.3 (range, 0.1 to 7.0) for patients who received CY alone (P = .01). Cyclophosphamide 95-97 CD34 molecule Homo sapiens 24-28 7541450-8 1995 All patients who received CY and Taxol reached a target level of 5 x 10(6) CD34+ cells/kg, as compared with five of nine patients (55.5%) who received CY alone (P = .03). Cyclophosphamide 26-28 CD34 molecule Homo sapiens 75-79 7525710-9 1994 CD34+ cells mobilized with granulocyte colony stimulating factor (G-CSF) or cyclophosphamide also bind VCAM-1 via VLA-4. Cyclophosphamide 76-92 CD34 molecule Homo sapiens 0-4 7525710-11 1994 VLA-4 function in CD34+ cells mobilized with G-CSF or cyclophosphamide is equivalent to steady state CD34+ cells. Cyclophosphamide 54-70 CD34 molecule Homo sapiens 18-22 8033053-12 1994 In patients treated with cyclophosphamide plus GM-CSF and cyclophosphamide alone, a median of 5.52 x 10(6) CD34+ cells/kg (range, 0.26-30.49) and 5.72 x 10(6) (range, 1.25-15.66) were collected, respectively. Cyclophosphamide 25-41 CD34 molecule Homo sapiens 107-111 8033053-12 1994 In patients treated with cyclophosphamide plus GM-CSF and cyclophosphamide alone, a median of 5.52 x 10(6) CD34+ cells/kg (range, 0.26-30.49) and 5.72 x 10(6) (range, 1.25-15.66) were collected, respectively. Cyclophosphamide 58-74 CD34 molecule Homo sapiens 107-111 7517260-3 1994 CY-VP-G products had a threefold higher median number of mononuclear cells collected, a fivefold higher median concentration of CD34 and LTC-IC and a threefold higher concentration of initial-CFC when compared with CY products. Cyclophosphamide 0-2 CD34 molecule Homo sapiens 128-132 7517260-6 1994 Analysis of the regression lines indicated that slopes of these regression lines were significantly different with a ratio of CD34 to initial CFC of 15:1 in the CY-VP-G products versus 5.2:1 with the CY products. Cyclophosphamide 161-163 CD34 molecule Homo sapiens 126-130 7517260-8 1994 Significant correlations of r = 0.9 (CY) and r = 0.53 (CY-VP-G) were observed when the initial CD34 concentration and the LTC-IC were compared. Cyclophosphamide 37-39 CD34 molecule Homo sapiens 95-99 7517260-8 1994 Significant correlations of r = 0.9 (CY) and r = 0.53 (CY-VP-G) were observed when the initial CD34 concentration and the LTC-IC were compared. Cyclophosphamide 55-57 CD34 molecule Homo sapiens 95-99 1279727-0 1992 Characterization of CD34+ cells mobilized to the peripheral blood during the recovery from cyclophosphamide chemotherapy. Cyclophosphamide 91-107 CD34 molecule Homo sapiens 20-24 7535498-6 1994 Our data suggest that the number of MNCs and CD34+ cells obtained after combined mobilization with cyclophosphamide and G-CSF can be used as predictor of the number of granulomonocytic progenitors. Cyclophosphamide 99-115 CD34 molecule Homo sapiens 45-49 1520868-4 1992 Neo-resistance gene transfer was documented also in a CD34+/cyclophosphamide-resistant precursor to granulocyte-macrophage colonies, an undifferentiated progenitor close to the hematopoietic stem cell. Cyclophosphamide 60-76 CD34 molecule Homo sapiens 54-58 7505211-4 1994 Comparative studies of CD34 cells showed that the percentage of CD34+ mononuclear cells was greatest in blood samples from patients following mobilization treatment with cyclophosphamide/etoposide/G-CSF averaging 2%. Cyclophosphamide 170-186 CD34 molecule Homo sapiens 64-68